Preparation of EBS Solusome nanovesicles

Preparation of Solusome concentrates using rotary evaporation

Determination of particle size and polydispersity index (PDI) in EBS-loaded Solusome nanovesicles before and after rotary evaporation

Freeze-drying of EBS Solusomes nanovesicles for characterization

Preparation of EBS-loaded Solusome nanovesicle-based oral lyophilisates

Computer-based experimental model

Characterization of the prepared oral lyophilisate formulations

Determination of the selected EBS-loaded Solusome nanovesicle-based oral lyophilisate formulation

Characterization of the selected EBS-loaded Solusome nanovesicle-based oral lyophilisate formulation

Drug–excipient compatibility evaluation

Differential scanning calorimetry (DSC)

Powder X-ray diffraction (PXRD)

In vivo pharmacokinetic study

Dose selection

Plasma sample preparation

HPLC analysis and pharmacokinetic calculations

Statistical analysis

Particle size and polydispersity index of the prepared EBS-loaded Solusome nanovesicles before and after rotary evaporation

Mean disintegration time and friability

Effect of gelatin on disintegration time and friability values

Effect of PVP K90 on disintegration time and friability values

Effect of glycine on disintegration time and friability values

Selected EBS-loaded Solusome nanovesicle-based oral lyophilisate formulation

Evaluation criteria for the selected EBS-loaded Solusome nanovesicle-based oral lyophilisate formulation (F7)

Evaluation of drug–excipient compatibility

Differential scanning calorimetry (DSC)

Powder X-ray diffraction (PXRD)

In vivo pharmacokinetics

Impact of independent factors on the friability values and disintegration time of oral lyophilisates based on EBS-loaded Solusome nanovesicles

Criteria for the selected EBS-loaded Solusome nanovesicle-based oral lyophilisate formulation (F7)

Conflict of interest

Ethical statements

Artificial Intelligence (AI) use

Funding

Author contributions

Author ORCIDs

Data availability